LINC01580: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC01580

NCBI ID: G101927129

Other Name(s): long intergenic non-protein coding RNA 1580 | Long intergenic non-protein coding RNA 1580, transcript variant 1

LINC01580: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

LINC01580 is a long non-coding RNA (lncRNA) that has been identified in various studies as having various functionalities, including regulating gene expression, influencing cellular processes, and participating in cellular signaling pathways. LINC01580 is a member of the LINC (Long Non-Protein-Coding RNAs) family, which has been identified as a potential drug target or biomarker in various diseases.

Disease-Related Functionality of LINC01580

LINC01580 has been shown to be involved in various cellular processes that are associated with various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

In cancer, LINC01580 has been shown to be involved in cell proliferation, angiogenesis, and drug resistance. For example, a study by Kim et al. (2020) found that LINC01580 was overexpressed in various cancer cell types and was associated with poor prognosis in cancer patients. Additionally, a study by Zhang et al. (2021) found that LINC01580 was downregulated in various cancer tissues and was associated with poor cancer outcomes.

In neurodegenerative diseases, LINC01580 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. For example, a study by Li et al. (2020) found that LINC01580 was downregulated in the brains of individuals with Alzheimer's disease and was associated with cognitive decline. Additionally, a study by Xu et al. (2021) found that LINC01580 was overexpressed in the brains of individuals with Parkinson's disease and was associated with motor neuron dysfunction.

In developmental disorders, LINC01580 has been shown to be involved in the development and progression of developmental disorders, including Down syndrome and Fragile X syndrome. For example, a study by Wang et al. (2020) found that LINC01580 was downregulated in the genomes of individuals with Down syndrome and was associated with various developmental delays. Additionally, a study by Liu et al. (2021) found that LINC01580 was overexpressed in the brains of individuals with Fragile X syndrome and was associated with cognitive and behavioral impairments.

Drug Targeting and Biomarker Potential

The functional roles of LINC01580 in various diseases make it an attractive drug target or biomarker. Several studies have shown that LINC01580 can be targeted by small molecules and antibodies to modulate its function and activity.

One potential drug target for LINC01580 is the PI3K/Akt signaling pathway, which is involved in various cellular processes, including cell survival, angiogenesis, and drug resistance. Several studies have shown that LINC01580 can interact with the PI3K/Akt signaling pathway and can modulate its activity. For example, a study by Zhao et al. (2020) found that LINC01580 can inhibit the PI3K/Akt signaling pathway and decrease cell proliferation and survival in various cancer cell types. Additionally, a study by Wang et al. (2021) found that LINC01580 can increase the sensitivity of cancer cells to chemotherapy by suppressing the PI3K/Akt signaling pathway.

Another potential drug target for LINC01580 is the NF-kappa signaling pathway, which is involved in cell growth, differentiation, and survival. Several studies have shown that LINC01580 can interact with the NF-kappa signaling pathway and can modulate its activity. For example, a study by Li et al. (2020) found that LINC01580 can inhibit the NF-kappa signaling pathway and decrease

Protein Name: Long Intergenic Non-protein Coding RNA 1580

More Common Targets